Medicalization and pharmaceuticalization at the intersections: A commentary on Bell and Figert (2012)

Social Science and Medicine

Volumn 75, Issue 12, 2012, Pages 2129-2130

  Williams, Simon ^a   Gabe, Jonathan ^b   Martin, Paul ^c  

^a UNIVERSITY OF WARWICK   (United Kingdom)

^b UNIVERSITY OF LONDON   (United Kingdom)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Medicalization; Pharmaceuticalization; Pharmaceuticals

Indexed keywords

ANTHROPOLOGY; BIOMEDICINE; BIOTECHNOLOGY; COST BENEFIT ANALYSIS; DEVELOPING COUNTRY; DRUG INDUSTRY; DRUG USE; MEDICAL INFORMATION; MEDICAL RESEARCH; NOTE; PRESCRIPTION; PUBLIC HEALTH; SOCIOLOGY;

DRUG THERAPY; HUMANS; TERMINOLOGY AS TOPIC;

EID: 84869500713     PISSN: 02779536     EISSN: 18735347     Source Type: Journal    
DOI: 10.1016/j.socscimed.2012.08.006     Document Type: Note

References (22)

1. Abraham J. Partial progress: governing the pharmaceutical industry and the NHS. Journal of Health Politics, Policy and Law 2009, 34:931-977.
2. Bell S.E., Figert A.E. Medicalization and pharmaceuticalization at the intersections: looking backward, sideways and forward. Social Science & Medicine 2012, 75:775-783.
3. Braithwaite J. Corporate crime in the pharmaceutical industry 1984, Routledge, London.
4. British Medical Association Boosting your brain power: Ethical aspects of cognitive enhancements 2007, BMA, London.
5. Busfield J. Globalization and the pharmaceutical industry revisited. International Journal of Health Services 2003, 33:581-605.
6. Busfield J. " A pill for every ill" : explaining the expansion in medicine use. Social Science & Medicine 2010, 70:934-941.
7. Chamberlain K., Madden K., Gabe J., Dew K., Norris P. Forms of resistance to medications within New Zealand households. Medische Anthropologie 2011, 23:299-308.
8. Clarke A., Mamo L., Fishman J.R., Shim J.K., Fosket J.R. Biomedicalization: technoscientific transformations of health, illness, and US biomedicine. American Sociological Review 2003, 68:161-194.
9. Biomedicalization: Technoscience, health and illness in the US 2010, Duke University Press, Durham. A. Clarke, L. Mamo, J.R. Fosket, J. Fishman, J.K. Shim (Eds.).
10. Dumit J., Greenslit N. Pharmaceutical cultures. Culture, Medicine and Psychiatry 2006, 30:127-134.
11. Gabe J., Bury M. Tranquillisers as a social problem. Sociological Review 1988, 36:320-352.
12. Gabe J., Bury M. Halcion nights: a sociological account of a medical controversy. Sociology 1996, 30:447-469.
13. Greeley H., Sahakian B., Harris J., Kessler R.C., Gazzaniga M., Campbell P., et al. Towards responsible use of cognitive-enhancing drugs by the healthy. Nature 2008, 456:702-705.
14. Hyman, S. (26th April 2012). The abandonment of the mentally ill by the pharmaceutical industry. Plenary talk at ENSN Final Conference " The mutual challenge of neuroscience and public health" , Goodenough College, University of London.
15. McGoey L., Reiss J., Whalberg A. The global health complex. Biosocieties 2011, 6:1-9.
16. Martin E. The pharmaceutical person. Biosocieties 2006, 1:273-287.
17. Martin E. Pharmaceutical virtue. Culture, Medicine and Psychiatry 2006, 30:157-174.
18. Pollock A. Transforming the critique of Big Pharma. Biosocieties 2011, 6:106-118.
19. Shah S. Body hunters: Testing new drugs on the world's poorest patients 2006, The New Press, London/New York.
20. Williams S.J., Martin P.A. Correspondence on cognitive enhancement drugs for the healthy: risks and benefits may turn out to be finely balanced. Nature 29th January 2009, 457(523).
21. Williams S.J., Martin P., Gabe J. The pharmaceuticalisation of society? A framework for analysis. Sociology of Health and Illness 2011, 33:710-723.
22. Williams S.J., Seale C., Boden S., Lowe P., Steinberg D.L. Waking up to sleepiness; modafinil, the media and the pharmaceuticalisation of everyday/night life. Sociology of Health and Illness 2008, 30:839-855.